Platelet transfusions and heparin therapy should be avoided in the management of suspected vaccine-induced immune thrombotic thrombocytopenia (VITT). A UK case series of 23 patients presenting with VITT after a first dose of the AstraZeneca COVID-19 vaccine said the combination of thrombosis and an apparent consumptive coagulopathy was a dilemma with respect to the benefits ...
VITT management recommendations: no to platelets and heparin
By Mardi Chapman
20 Apr 2021